Nuclea Biotechnologies Taps New CFO
 |
PITTSFIELD, Mass. — Nuclea Biotechnologies has hired Bern Whitney as its chief financial officer.
Whitney brings more than 30 years’ experience to his position at Nuclea. He has served as CFO, and as senior financial management, in numerous fast-growth companies ranging in size from pre-public entities to billion-dollar multinationals. During that time, he raised over $650 million of capital in initial public, follow-on, and debt offerings.
Highlighting the depth of his experience, Whitney’s previous responsibilities have included controllership, treasury, manufacturing and site operations, business development (mergers and acquisitions), corporate communications, information technology, legal affairs, and human resources.
He is currently a partner at FLG Partners, a leading CFO advisory firm, and has served on both public company and private entity boards.
“Bern brings a wealth of experience to Nuclea’s team,” said Patrick Muraca, president and CEO of Nuclea. “He will provide critical support for us as we continue on our path to commercialization. I want to thank Bob Pierce, our previous CFO, for his dedication and service to Nuclea."
“I believe Nuclea is poised for success and I look forward to supporting them in their move from a R&D development organization to a commercial operation," Whitney said.
Nuclea Biotechnologies is headquartered in Pittsfield with additional operations in Worcester and Cambridge, Mass. Nuclea has developed and is commercializing unique diagnostic tests for colon, breast, leukemia, lung and prostate cancer, as well as for diabetes and other metabolic syndromes. Nuclea also performs research leading to novel molecular oncology companion diagnostics for the pharmaceutical and biotechnology industries.
